Sobi's soaring revenues beat estimates

20 February 2019
sobi-logo-big

Swedish Orphan Biovitrum (STO: SOBI), the Nordic biotech company known as Sobi, has published a financial summary for the fourth quarter and 2018 as a whole that paints a picture of rapid growth.

Revenue at the company was 2.57 billion Swedish kronor ($280 million) for the fourth quarter, growing 37% on the same period of 2017, while the full-year sales figure was 9.14 billion kronor, a 40% jump.

Earnings before interest, tax and amortization (EBITA) for the quarter hit 916 million kronor, up 48% and beating analyst estimates of 831 million kronor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology